The company is focused on developing best-in-class monoclonal antibodies that block the Junction Adhesion Molecule JAM-C and the extracellular matrix-related protein. This treatment is designed for patients who do not respond to traditional cancer therapies. Abologix's monoclonal antibody treatment enables healthcare providers to treat patients with several oncological medical indications.